About Dr. Gao Pingjin
Dr. Gao Pingjin is a Professor, Doctoral Supervisor, and one of China's foremost clinical scientists and academic leaders in the field of hypertension and cardiovascular metabolic disease, based at the Department of Cardiovascular Medicine (Cardiology), Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. He serves as Director of the Shanghai Institute of Hypertension — one of China's most influential hypertension research and clinical centers — and is recognized nationally and internationally as a leading authority on the pathophysiology, diagnosis, and management of hypertension, hypertensive organ damage, and the intersection of hypertension with metabolic disease, renal disease, and cardiovascular risk.
Dr. Gao's career has been defined by a commitment to translating advances in hypertension science into better clinical outcomes for patients — both through his own research program at the Shanghai Institute of Hypertension and through his leadership of national clinical guidelines, epidemiological studies, and quality improvement initiatives that have shaped hypertension management practice across China. His research has addressed some of the most clinically important questions in hypertension medicine: the optimal blood pressure targets for patients with different risk profiles and comorbidities, the mechanisms of hypertensive end-organ damage in the heart, kidney, and brain, the role of aldosterone and the renin-angiotensin-aldosterone system (RAAS) in resistant hypertension, the relationship between hypertension and metabolic syndrome, and the epidemiology of hypertension and its complications in Chinese populations.
For international patients — particularly expatriates living in Shanghai and medical tourists from regions where hypertension management is fragmented or where access to specialist hypertension expertise is limited — Dr. Gao offers a level of clinical depth and scientific rigor in the evaluation and management of hypertension that is rarely available outside major academic hypertension centers. His particular expertise in resistant hypertension, secondary hypertension, hypertensive organ damage assessment, and the optimization of antihypertensive regimens in patients with complex comorbidities makes him an invaluable resource for patients whose blood pressure has not been adequately controlled despite multiple medications, or who have developed complications of hypertension requiring specialist evaluation.
Hospital Affiliation: Shanghai Institute of Hypertension, Ruijin Hospital
Ruijin Hospital (瑞金医院), affiliated with Shanghai Jiao Tong University School of Medicine, is one of Shanghai's oldest and most respected academic medical institutions, founded in 1907 and consistently ranked among China's top hospitals. Its Department of Cardiovascular Medicine is a high-volume, multidisciplinary cardiology program with particular national and international recognition in the field of hypertension, where the Shanghai Institute of Hypertension — housed within Ruijin Hospital — has been a leading center for hypertension research, clinical care, and guideline development for decades.
The Shanghai Institute of Hypertension is equipped with a comprehensive hypertension diagnostic infrastructure: 24-hour ambulatory blood pressure monitoring (ABPM), home blood pressure monitoring programs, advanced echocardiographic assessment of hypertensive heart disease (left ventricular hypertrophy, diastolic dysfunction, left atrial enlargement), renal function and proteinuria assessment, carotid intima-media thickness (CIMT) measurement and carotid ultrasound, pulse wave velocity (PWV) and augmentation index measurement for arterial stiffness assessment, fundoscopic evaluation for hypertensive retinopathy, and a full secondary hypertension workup including adrenal imaging, aldosterone-to-renin ratio, renal artery Doppler ultrasound, and genetic testing for monogenic hypertension syndromes where indicated.
The institute maintains active research collaborations with hypertension centers across China and internationally, participates in major international hypertension clinical trials, and has contributed to the development of Chinese hypertension management guidelines through the Chinese Society of Cardiology and the Chinese Hypertension League. For international patients, Ruijin Hospital offers access to specialist hypertension expertise and a comprehensive diagnostic evaluation at costs substantially below those of equivalent specialist care in Western healthcare systems.
Clinical Specialties: What Dr. Gao Pingjin Treats
- Resistant and refractory hypertension — systematic evaluation and management of patients whose blood pressure remains above target despite three or more antihypertensive medications at optimal doses including a diuretic; identification and correction of contributing factors including medication non-adherence, white-coat effect, obstructive sleep apnea, dietary sodium excess, and drug interactions; optimization of antihypertensive regimen; evaluation for secondary causes; consideration of device-based therapies including renal denervation for appropriate candidates
- Secondary hypertension — comprehensive evaluation for identifiable causes of hypertension including primary aldosteronism (Conn's syndrome), renovascular hypertension (renal artery stenosis), renal parenchymal disease, pheochromocytoma and paraganglioma, Cushing's syndrome, thyroid and parathyroid disorders, obstructive sleep apnea, and monogenic hypertension syndromes; adrenal vein sampling coordination for primary aldosteronism subtyping; multidisciplinary management planning with endocrinology, nephrology, and urology
- Hypertensive organ damage assessment and management — comprehensive evaluation of hypertension-mediated organ damage (HMOD) in the heart (left ventricular hypertrophy, diastolic dysfunction, heart failure with preserved ejection fraction), kidney (chronic kidney disease, proteinuria, hypertensive nephrosclerosis), brain (white matter lesions, lacunar infarcts, cognitive impairment), and vasculature (arterial stiffness, carotid atherosclerosis, peripheral arterial disease); risk stratification and treatment intensification based on HMOD burden
- Hypertension in the context of metabolic syndrome and diabetes — integrated management of hypertension coexisting with obesity, dyslipidemia, insulin resistance, and type 2 diabetes; optimization of antihypertensive therapy with attention to metabolic neutrality and cardiorenal protective effects; coordination with endocrinology for comprehensive cardiovascular metabolic risk reduction
- Hypertension in chronic kidney disease — blood pressure management in patients with CKD stages 1–5, with attention to the dual goals of cardiovascular risk reduction and slowing of CKD progression; optimization of RAAS blockade; management of hypertension in dialysis patients; coordination with nephrology for integrated cardiorenal care
- Hypertension in pregnancy and women of childbearing age — management of chronic hypertension in pregnancy, preeclampsia risk assessment and prevention, postpartum hypertension management, and antihypertensive therapy selection in women planning pregnancy
- Cardiovascular risk assessment and primary prevention — comprehensive cardiovascular risk stratification using validated risk scores adapted for Chinese populations; assessment and management of multiple cardiovascular risk factors including hypertension, dyslipidemia, diabetes, smoking, and obesity; lifestyle intervention counseling; initiation and optimization of preventive pharmacotherapy
- Hypertension management in elderly patients — blood pressure target selection and antihypertensive regimen optimization in older adults, with attention to orthostatic hypotension, frailty, polypharmacy, and cognitive function; isolated systolic hypertension management
Research Leadership and Academic Contributions
Dr. Gao Pingjin's research program at the Shanghai Institute of Hypertension has produced a substantial body of work that has shaped hypertension science and clinical practice in China and internationally. His research has encompassed the epidemiology of hypertension and its complications in Chinese populations, the mechanisms of hypertensive end-organ damage, the role of the RAAS and aldosterone in resistant and secondary hypertension, the relationship between hypertension and metabolic disease, and the clinical pharmacology of antihypertensive agents in Chinese patients.
He has served as principal investigator or co-investigator on multiple major national and international hypertension clinical trials, and has contributed to the development of Chinese hypertension management guidelines through the Chinese Society of Cardiology and the Chinese Hypertension League. His publications in peer-reviewed journals — including contributions to Hypertension, Journal of Hypertension, European Heart Journal, Journal of the American College of Cardiology, and Chinese Medical Journal — have been widely cited and have contributed to the international evidence base for hypertension management. His leadership of the Shanghai Institute of Hypertension has established it as one of China's premier centers for hypertension research and clinical excellence, attracting patients and research collaborators from across China and internationally.
Why International Patients Choose Dr. Gao Pingjin and Ruijin Hospital
International patients — including expatriates living in Shanghai and medical tourists from North America, Europe, Southeast Asia, and the Middle East — seek consultation with Dr. Gao Pingjin for a range of reasons that reflect both the clinical depth of his expertise and the practical advantages of accessing specialist hypertension care at Ruijin Hospital.
For patients with resistant hypertension — blood pressure that remains above target despite multiple medications — Dr. Gao's systematic approach to identifying and correcting contributing factors, ruling out secondary causes, and optimizing the antihypertensive regimen frequently achieves blood pressure control that has eluded less specialized management. The comprehensive secondary hypertension workup available at Ruijin Hospital — including adrenal imaging, aldosterone-to-renin ratio testing, adrenal vein sampling, renal artery imaging, and genetic testing — enables the identification of treatable secondary causes that, when corrected, can dramatically improve blood pressure control and reduce the need for multiple medications.
For patients with hypertensive organ damage — left ventricular hypertrophy, diastolic dysfunction, chronic kidney disease, or cerebrovascular disease attributable to poorly controlled hypertension — Dr. Gao's expertise in HMOD assessment and his ability to integrate the findings into a comprehensive treatment strategy that addresses both blood pressure control and organ protection provides a level of clinical sophistication that is difficult to access outside major academic hypertension centers.
For expatriates living in Shanghai who require ongoing specialist hypertension management, Dr. Gao and the Shanghai Institute of Hypertension offer continuity of care with a world-class hypertension specialist — including 24-hour ABPM, home blood pressure monitoring programs, and regular follow-up — that provides a standard of hypertension care equivalent to or exceeding what is available in their home countries.
The cost of specialist hypertension consultation and comprehensive diagnostic evaluation at Ruijin Hospital is substantially below that of equivalent specialist care in Western healthcare systems, and access to Dr. Gao's clinic can typically be arranged within days through CMCS.
What to Expect at Your Consultation
Consultations with Dr. Gao Pingjin at Ruijin Hospital arranged through CMCS begin with a comprehensive review of all prior blood pressure records — including home blood pressure logs and prior ABPM reports where available — current antihypertensive medications and prior medication history, relevant laboratory results (renal function, electrolytes, aldosterone-to-renin ratio, thyroid function, fasting glucose and lipids, urinalysis and urine protein quantification), prior cardiac imaging (echocardiography, ECG), and the patient's cardiovascular risk factor profile, comorbidities, and family history. CMCS will arrange certified translation of all medical records and investigation results in advance of the consultation.
Dr. Gao will assess the severity and pattern of hypertension, evaluate the likelihood of secondary causes, assess the burden of hypertensive organ damage, stratify overall cardiovascular risk, and outline a comprehensive management plan including antihypertensive regimen optimization, lifestyle modification recommendations, further diagnostic investigations where indicated, and a follow-up schedule. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Gao's team and the patient's home cardiologist or general practitioner for continuity of care.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking hypertension and cardiovascular metabolic consultation with Dr. Gao Pingjin at Ruijin Hospital. Our services include priority consultation scheduling with Dr. Gao and the Shanghai Institute of Hypertension team, certified medical record and investigation result translation, coordination of 24-hour ABPM and other diagnostic investigations, on-site interpretation throughout the consultation, and written English-language reporting of all findings and recommendations. CMCS will also facilitate direct communication between Dr. Gao's team and the patient's home physicians to ensure seamless integration of the Ruijin Hospital assessment into the patient's ongoing cardiovascular care.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 commenti